Vaccine News and Research

Latest Vaccine News and Research

Research on viral RNA may help scientists develop treatments against infectious diseases

In an article published in the scientific journal Nature, a University of Colorado School of Medicine researcher and colleagues explain how RNA molecules found in certain viruses mimic the shape of other molecules as part of a strategy to 'hijack' the cell and make more viruses.

10 Jun 2014

Combined MMRV vaccine slightly increases risk of febrile seizures in children

The combined measles-mumps-rubella-varicella (MMRV) vaccine shows a slightly increased risk of febrile seizures in children, compared with the previously separate vaccines for MMR and varicella (chickenpox) (MMR+V), according to an article in CMAJ (Canadian Medical Association Journal).

10 Jun 2014

Researchers move closer to establishing link between GAD65 protein and type 1 diabetes

Researchers are a step closer to establishing the link between a protein with a split personality and type 1 diabetes.

10 Jun 2014

S. pneumoniae is major cause of severe pneumonia in Gambian children

Researchers have published a detailed survey of children with pneumonia in the Gambia, which reveals that Streptococcus pneumoniae is the predominant aetiological agent and that multiple pathogens are present in at least half of cases.

9 Jun 2014

Protein-kinase interactions offer a new way to fight antimalarial drug resistance

When it comes to the emergence of antimalarial drug resistance, it's not a question of 'if' but 'when'. In order to keep up with the quickly evolving Plasmodium parasite - the cause of malaria - new ways to treat and control the disease must be found.

9 Jun 2014

Batu Biologics reports FDA development plans for cancer immunotherapeutic vaccine ValloVax

Batu Biologics announced today FDA development plans for its patent-pending lead product, ValloVax, a cancer immunotherapeutic "vaccine" that specifically targets the tumor blood vessels (endothelium).

9 Jun 2014

Progress in constructing protein nanomachines

A route for constructing protein nanomachines engineered for specific applications may be closer to reality.

6 Jun 2014

Studies confirm importance of men seeing physician on regular basis

For many men being a father is about staying strong as they protect and care for their family. Some men see going to the doctor as a weakness or nuisance, but protecting your health is one of the best things a father can do for his family.

6 Jun 2014

New TB blood test could eliminate unnecessary treatment

A new screening process for tuberculosis (TB) infections in Canadian prisons could mean that more than 50 per cent of those screened won't undergo unnecessary treatment due to false positives.

6 Jun 2014

Flu vaccination of healthcare workers protects broader community, shows study

For every 15 healthcare providers who receive the influenza vaccination, one fewer person in the community will contract an influenza-like illness, according to a study using California public health data from 2009 - 2012.

5 Jun 2014

New vaccine effective at preventing lung cancer in mice

Tweaking a protein expressed by most liver cancer cells has enabled scientists to make a vaccine that is exceedingly effective at preventing the disease in mice.

4 Jun 2014

PsiOxus Therapeutics presents positive study results of anti-cancer vaccine Enadenotucirev at ASCO Annual Meeting

PsiOxus Therapeutics, Ltd. (PsiOxus), an award-winning biotechnology company developing innovative, novel treatments for cancer, announced that updates for its on-going international multicentre clinical program of the oncolytic vaccine enadenotucirev (previously known as ColoAd1) were presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

4 Jun 2014

Researchers figure out way to disable a part of SARS virus

A Purdue University-led research team has figured out how to disable a part of the SARS virus responsible for hiding it from the immune system; a critical step in developing a vaccine against the deadly disease.

4 Jun 2014

Salk Institute receives $25 million for cutting-edge biological research

The Salk Institute for Biological Studies has received a $25 million gift from San Diego philanthropist and former Salk trustee Conrad T. Prebys to support cutting-edge biological research on a wide range of diseases.

3 Jun 2014

AMRI agrees to acquire OsoBio for $110 million

AMRI today announced that it has signed a definitive agreement to acquire all of the outstanding membership interests of Oso Biopharmaceuticals Manufacturing, LLC for $110 million in cash.

2 Jun 2014

Updated data from ImmunoCellular ICT-107 trial in patients with newly diagnosed GBM presented at ASCO 2014

ImmunoCellular Therapeutics, Ltd. announced that updated efficacy and safety data from the phase II trial of dendritic cell-based immunotherapeutic vaccine ICT-107 in patients with newly diagnosed glioblastoma multiforme (GBM) were presented at the 2014 American Society for Clinical Oncology (ASCO) annual meeting in Chicago.

2 Jun 2014

Immune system-boosting therapy slows recurrence of glioblastoma multiforme

A multicenter team of investigators, led by researchers from the Cedars-Sinai Department of Neurosurgery, the Cedars-Sinai Maxine Dunitz Neurosurgical Institute and Dana-Farber Cancer Institute in Boston, have found in a Phase II clinical trial that an immune system-boosting therapy slowed the recurrence of glioblastoma multiforme, or GBM, the most common and deadly malignant brain tumor.

2 Jun 2014

Morphogenesis announces publication of new book, Cancer Vaccines: Methods and Protocols

Drs. Michael J.P. Lawman and Patricia D. Lawman, founders of the Tampa-based biotech firm Morphogenesis Inc., announce the publication of "Cancer Vaccines: Methods and Protocols," the most definitive work to date in the promising field of cancer vaccines.

31 May 2014

Astellas seeks marketing approval for Flublok recombinant influenza vaccine in Japan

Protein Sciences Corporation announced today that Astellas Pharma has submitted an application for marketing approval of recombinant influenza HA vaccine ASP7374 (marketed as Flublok® in the United States by Protein Sciences) to the Ministry of Health, Labour and Welfare in Japan for the prevention of influenza.

31 May 2014

Inovio Pharmaceuticals’ reverse stock split to become effective on June 5, 2014

Inovio Pharmaceuticals, Inc. today announced that its previously announced 1-for-4 reverse stock split shall become effective at 5 P.M., Thursday, June 5, 2014, and trading of the Company's common stock on a post-reverse split basis shall commence on Friday, June 6, 2014.

30 May 2014